August 4th, 2011
Easy Come, Easy Go? ESC to Review Dronedarone’s Role in AF Guidelines
Less than a year after speeding into the European Society of Cardiology’s atrial fibrillation guidelines with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF will be reconsidered.
“The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory authorities have revised the labelling for dronedarone,” the ESC announced today.
Since the publication of the ESC guidelines last September, dronedarone has sparked concerns related to several cases of severe liver injury. Then the PALLAS trial was terminated early due to an increase in cardiovascular events in patients with permanent AF treated with dronedarone.